Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
5.19
+0.59 (12.83%)
At close: Nov 26, 2025, 4:00 PM EST
5.12
-0.07 (-1.35%)
After-hours: Nov 26, 2025, 7:59 PM EST
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$69,566
Profits / Employee
-$512,435
Market Cap
237.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160 | 58 | 56.86% |
| Dec 31, 2023 | 102 | 28 | 37.84% |
| Dec 31, 2022 | 74 | 26 | 54.17% |
| Dec 31, 2021 | 48 | 22 | 84.62% |
| Dec 31, 2020 | 26 | 10 | 62.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CAPR News
- 2 days ago - Martin Shkreli Takes Aim At Capricor — Stock Sinks - Benzinga
- 15 days ago - Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel - GlobeNewsWire
- 26 days ago - Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 - GlobeNewsWire
- 7 weeks ago - Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewsWire
- 2 months ago - Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 - Seeking Alpha
- 2 months ago - Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway - Seeking Alpha
- 2 months ago - Capricor Therapeutics, Inc. - Special Call - Seeking Alpha